Cellectar Biosciences Shares Drop After $6M Public Offering Prices

Dow Jones

Jul 01, 2025

By Chris Wack

Cellectar Biosciences shares were 30% lower, at $4.98, after the company priced an underwritten public offering for proceeds of $6 million.

The stock hit its 52-week low of $4.90 earlier in the session, and is down 93% in the past 12 months.

The biopharmaceutical company said the offering is comprised of 865,000 class A units and 335,000 class B units. The price per class A unit is $5, and the price per class B unit is $4.99999.

The warrants will have an exercise price of $5.25 per share, will be exercisable upon issuance, and have a term expiring five years from issuance.

The closing of the offering is expected to take place on or about Wednesday.

Cellectar has granted the underwriter a 45-day option to buy up to 180,000 additional shares and/or 180,000 warrants, solely to cover over-allotments, if any, at the public offering price, less the underwriting discounts and commissions.

The company currently intends to use the proceeds of the offering for general corporate purposes, including working capital and operating expenses, and to initiate a Phase 1b clinical study of compound CLR 121125 in triple-negative breast cancer.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

July 01, 2025 10:13 ET (14:13 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2548007271"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548007271\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548007271?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-01 22:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548007271","market":"hk","top_or_hot":-1,"title":"Cellectar Biosciences Shares Drop After $6M Public Offering Prices","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CLRBZ\">Cellectar Biosciences</a> shares were 30% lower, at $4.98, after the company priced an underwritten public offering for proceeds of $6 million. \n</p>\n<p>\n  The stock hit its 52-week low of $4.90 earlier in the session, and is down 93% in the past 12 months. \n</p>\n<p>\n  The biopharmaceutical company said the offering is comprised of 865,000 class A units and 335,000 class B units. The price per class A unit is $5, and the price per class B unit is $4.99999. \n</p>\n<p>\n  The warrants will have an exercise price of $5.25 per share, will be exercisable upon issuance, and have a term expiring five years from issuance. \n</p>\n<p>\n  The closing of the offering is expected to take place on or about Wednesday. \n</p>\n<p>\n  Cellectar has granted the underwriter a 45-day option to buy up to 180,000 additional shares and/or 180,000 warrants, solely to cover over-allotments, if any, at the public offering price, less the underwriting discounts and commissions. \n</p>\n<p>\n  The company currently intends to use the proceeds of the offering for general corporate purposes, including working capital and operating expenses, and to initiate a Phase 1b clinical study of compound CLR 121125 in triple-negative breast cancer. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 01, 2025 10:13 ET (14:13 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cellectar Biosciences Shares Drop After $6M Public Offering Prices</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCellectar Biosciences Shares Drop After $6M Public Offering Prices\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-01 22:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CLRBZ\">Cellectar Biosciences</a> shares were 30% lower, at $4.98, after the company priced an underwritten public offering for proceeds of $6 million. \n</p>\n<p>\n  The stock hit its 52-week low of $4.90 earlier in the session, and is down 93% in the past 12 months. \n</p>\n<p>\n  The biopharmaceutical company said the offering is comprised of 865,000 class A units and 335,000 class B units. The price per class A unit is $5, and the price per class B unit is $4.99999. \n</p>\n<p>\n  The warrants will have an exercise price of $5.25 per share, will be exercisable upon issuance, and have a term expiring five years from issuance. \n</p>\n<p>\n  The closing of the offering is expected to take place on or about Wednesday. \n</p>\n<p>\n  Cellectar has granted the underwriter a 45-day option to buy up to 180,000 additional shares and/or 180,000 warrants, solely to cover over-allotments, if any, at the public offering price, less the underwriting discounts and commissions. \n</p>\n<p>\n  The company currently intends to use the proceeds of the offering for general corporate purposes, including working capital and operating expenses, and to initiate a Phase 1b clinical study of compound CLR 121125 in triple-negative breast cancer. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 01, 2025 10:13 ET (14:13 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2548007271","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548007271","pubTimestamp":1751379180,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Cellectar Biosciences shares were 30% lower, at $4.98, after the company priced an underwritten public offering for proceeds of $6 million.The stock hit its 52-week low of $4.90 earlier in the session, and is down 93% in the past 12 months.The biopharmaceutical company said the offering is comprised of 865,000 class A units and 335,000 class B units. The price per class A unit is $5, and the price per class B unit is $4.99999.The warrants will have an exercise price of $5.25 per share, will be exercisable upon issuance, and have a term expiring five years from issuance.The closing of the offering is expected to take place on or about Wednesday.Cellectar has granted the underwriter a 45-day option to buy up to 180,000 additional shares and/or 180,000 warrants, solely to cover over-allotments, if any, at the public offering price, less the underwriting discounts and commissions.The company currently intends to use the proceeds of the offering for general corporate purposes, including wor","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CLRB":"Cellectar Biosciences Inc."},"translate_title":"Cellectar Biosciences公开发行价600万美元后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLRB":1},"content_text":"By Chris Wack \n\n\n \n\n\nCellectar Biosciences shares were 30% lower, at $4.98, after the company priced an underwritten public offering for proceeds of $6 million. \n\n\n  The stock hit its 52-week low of $4.90 earlier in the session, and is down 93% in the past 12 months. \n\n\n  The biopharmaceutical company said the offering is comprised of 865,000 class A units and 335,000 class B units. The price per class A unit is $5, and the price per class B unit is $4.99999. \n\n\n  The warrants will have an exercise price of $5.25 per share, will be exercisable upon issuance, and have a term expiring five years from issuance. \n\n\n  The closing of the offering is expected to take place on or about Wednesday. \n\n\n  Cellectar has granted the underwriter a 45-day option to buy up to 180,000 additional shares and/or 180,000 warrants, solely to cover over-allotments, if any, at the public offering price, less the underwriting discounts and commissions. \n\n\n  The company currently intends to use the proceeds of the offering for general corporate purposes, including working capital and operating expenses, and to initiate a Phase 1b clinical study of compound CLR 121125 in triple-negative breast cancer. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 01, 2025 10:13 ET (14:13 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}